Navigation Links
CEL-SCI Corporation Reports First Quarter 2010 Financial Results
Date:2/16/2010

VIENNA, Va., Feb. 16 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) reports financial results for the quarter ended December 31, 2009.

CEL-SCI reported that net income available to shareholders for the quarter ended December 31, 2009 was $19,159,517 versus a loss of ($2,173,513) during the same quarter in fiscal year 2009. Net income per share, basic was $0.10 for the quarter ended December 31, 2009 versus a loss of ($0.02) during the same quarter in fiscal year 2009.  The operating loss for the quarter ended December 31, 2009 was ($4,252,849) versus an operating loss of ($2,551,823) during the same quarter in fiscal year 2009. The gain on net income available to shareholders for the quarter ended December 31, 2009 is due to derivative accounting.

R&D expenses for the quarter ended December 31, 2009 totaled $2,805,127 versus R&D expenses of $1,410,753 for the same quarter in fiscal year 2009.  R&D expenses increased due to higher costs associated with preparing for the Company's upcoming Phase III clinical trial of its cancer drug Multikine®.

Geert Kersten, Chief Executive Officer said, "We concluded December 31, 2009 quarter in the strongest financial condition ever, with more than $36 million in cash and cash equivalents, allowing us to self-fund our upcoming pivotal Phase III study with our cancer drug Multikine.  We are excited that we are in position to move Multikine through the clinic without losing rights to any of the major markets and to continue to develop our L.E.A.P.S.™ technology platform in areas such as H1N1 and Rheumatoid Arthritis."

Multikine is the first immunotherapeutic agent being developed as a first-line standard of care treatment for cancer.  It is administered prior to any other cancer therapy because that is the period when the anti-tumor immune response can still be fully activated.  Once the patient has advanced disease, or had surgery or has received radiation and/or chemotherapy, the immune system is severely weakened and is less able to mount an effective anti-tumor immune response.  Other immunotherapies are administered after the patient has received chemotherapy and/or radiation therapy, which can limit their effectiveness.

In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery.  The U.S. Food and Drug Administration (FDA) gave the go-ahead for a Phase III clinical trial with Multikine in January 2007 and granted orphan drug status to Multikine in the neoadjuvant therapy of squamous cell carcinoma (cancer) of the head and neck in May 2007.  Thereafter CEL-SCI built a dedicated manufacturing facility for Multikine which is now completed and fully validated.

About CEL-SCI Corporation

CEL-SCI Corporation is developing products that empower immune defenses. Its lead product Multikine is being readied for a global Phase III trial in advanced primary head and neck cancer. CEL-SCI is also developing an immunotherapy (LEAPS-H1N1-DC) to treat H1N1 hospitalized patients and a vaccine (CEL-2000) for Rheumatoid Arthritis using its L.E.A.P.S. technology platform.  The LEAPS-H1N1-DC treatment involves non-changing regions of H1N1 Pandemic Flu, Avian Flu (H5N1), and the Spanish Flu as CEL-SCI scientists are very concerned about the creation of a new more virulent hybrid virus through the combination of H1N1 and Avian Flu, or maybe Spanish Flu.  This investigational treatment is currently being tested in a clinical study at Johns Hopkins University.  The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.

For more information, please visit www.cel-sci.com .

    
    
    
    
                                   CEL-SCI CORPORATION
                       CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                       (unaudited)
                                                       Three Months Ended
                                                           December 31,
                                                     2009                2008
                                                     ----                ----
    REVENUE:
    
      Rent income                                   $30,000                $-
                                                  ---------         ---------
    
                   Total revenue                     30,000                 -
     EXPENSES:
      Research and development, excluding 
       depreciation of $99,583 and $64,523 
       included below                             2,805,127         1,410,753
      Depreciation and amortization                 119,581            85,944
      General and administrative                  1,358,141         1,055,126
                                                  ---------         ---------
    
                   Total expenses                 4,282,849         2,551,823
                                                  ---------         ---------
    
      LOSS FROM OPERATIONS                      (4,252,849)        (2,551,823)
    
     GAIN ON DERIVATIVE INSTRUMENTS              23,340,267           391,689
    
     INTEREST INCOME                                110,219            71,237
    
     INTEREST EXPENSE                               (38,120)          (84,616)
                                                    -------           -------
    
     NET INCOME (LOSS) BEFORE INCOME TAXES       19,159,517        (2,173,513)
    
     INCOME TAX PROVISION                                 -                 -
                                                    -------           -------
    
     NET INCOME (LOSS) AVAILABLE TO
      COMMON SHAREHOLDERS                       $19,159,517       $(2,173,513)
                                                ===========       ===========
    
     NET INCOME (LOSS) PER COMMON SHARE-BASIC         $0.10            $(0.02)
                                                      =====            ======
    
     NET INCOME (LOSS) PER COMMON SHARE-DILUTED       $0.02            $(0.02)
                                                      =====            ======
    
     WEIGHTED AVERAGE COMMON
       SHARES OUTSTANDING-BASIC                 194,959,814       122,215,334
                                                ===========       ===========
     WEIGHTED AVERAGE COMMON
       SHARES OUTSTANDING-DILUTED               256,198,162       122,215,334
                                                ===========       ===========
    
    
    

SOURCE CEL-SCI Corporation

RELATED LINKS
http://www.cel-sci.com

'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
4. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
5. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
6. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI Corporation Announces 2007 Financial Results
9. CEL-SCI Corporation Reports First Quarter Financial Results
10. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
11. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... Norgine B.V. und ... entscheidenden Meilenstein durch diese Veröffentlichung zur  Hepatischen ... um Patientenresultate  bei Verdauungs- und Lebererkrankungen zu ... Verständnis der Hepatischen Enzephalopathie bei und hebt ... Enzephalopathie in der Öffentlichkeit zu schaffen und ...
(Date:5/2/2016)... 2, 2016  While nearly three-quarters of Americans (71%) ... on their health, only about half report taking any ... results of a new survey announced today by Hologic ... of National Osteoporosis Month, Hologic is raising awareness of ... 56 million Americans. Osteoporosis is a disease ...
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
Breaking Medicine Technology:
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... Nike ... to junior rugby in San Diego. Willis, founder of Elite Rugby Camps and current ... coaches and players every year since 2009. , “I’m excited for our eighth ...
(Date:5/4/2016)... ... 04, 2016 , ... All-Star Insurance of Northeast TX has ... of their local community. The agency pledges to select a new beneficiary every ... to bring awareness to important local causes with fundraising and other support, by ...
(Date:5/4/2016)... ... 2016 , ... Dr. Elyson and Dr. Assili, dentist in Northridge , ... tooth removal, a common dental procedure, is performed for many adolescents and young adults ... in risks of complications. By providing wisdom tooth removal surgery at their office, Dr. ...
(Date:5/4/2016)... ... , ... Francesca Loparco, Co-Founder of Queen City Dream Cars, an exotic car ... procedure at Christenbury Eye Center. The entrepreneur struggled with her computer, riding horses ... day as her in-office consultation and eye exam. Francesca’s eyesight was restored to 20/20 ...
(Date:5/4/2016)... TX (PRWEB) , ... May 04, 2016 , ... ... Nightstick all-LED multi-function small and compact tactical (6.7 inch) dual-light flashlights in models ... Las Vegas, model NSP-9842XL (average retail starting at $59.95) uses 2 included CR-123 ...
Breaking Medicine News(10 mins):